Results 61 to 70 of about 28,321 (229)
Myeloproliferative neoplasms: a review of diagnostic criteria and clinical aspects [PDF]
, 2010 Chronic myeloproliferative disorders, currently called myeloproliferative neoplasms (MPN), according to the 4th edition of the World Health Organization (WHO) classification are clonal diseases of hematopoietic stem cells, in which there is increased ...
Chauffaille, Maria de Lourdes Lopes Ferrari
core +1 more source
Cancer, Volume 132, Issue 11, 1 June 2026.Abstract Background Mutations in cytokine receptor and JAK/STAT; Cy‐JAK/STAT) signaling genes drive myeloproliferative neoplasms (MPNs) but remain incompletely characterized in acute myeloid leukemia (AML). The authors evaluated the prevalence, clinical presentation, and prognostic significance of Cy‐JAK/STAT pathway mutations in patients with AML and ...
Moath Albliwi +22 more
wiley +1 more source
Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms. [PDF]
, 2014 Myeloproliferative neoplasms (MPNs) are clonal hematological diseases in which cells of the myelo-erythroid lineage are overproduced and patients are predisposed to leukemic transformation.
de Haan, Gerald +3 more
core +1 more source
International Journal of Gynecology &Obstetrics, Volume 173, Issue 3, Page 1183-1196, June 2026.Abstract Background The prevalence of iron deficiency with anemia and iron deficiency without anemia (IDWA) during pregnancy have not been summarized, and evidence of the direct association of IDWA with adverse perinatal outcomes (APO) are unknown.
Lucky O. Lawani +6 more
wiley +1 more source
Myelopathy due to Spinal Extramedullary Hematopoiesis in a Patient with Polycythemia Vera
Case Reports in Orthopedics, 2017 Extramedullary hematopoiesis (EMH) occasionally occurs in patients exhibiting hematological disorders with decreased hematopoietic efficacy. EMH is rarely observed in the spinal epidural space and patients are usually asymptomatic.
Shuhei Ito +10 more
doaj +1 more source
eJHaem, Volume 7, Issue 3, June 2026.ABSTRACT Introduction Clinical benefit measures and surrogates for leukaemic transformation or overall survival are scarce in MF. Circulating myeloblast (CMB) counts have the biological plausibility to indicate disease evolution, but they are still determined by an outdated approach with microscopic examination and fixed cut‐offs.
Malak Tamer Abdelmaksoud +6 more
wiley +1 more source
Haematologica, 2011 We tested the hypothesis that levels of pentraxin high sensitivity C-reactive protein and pentraxin 3 might be correlated with cardiovascular complications in patients with essential thrombocythemia and polycythemia vera.
Tiziano Barbui +15 more
doaj +1 more source
The symptomatic treatment of polycythemia vera [PDF]
, 1933 Thesis (M.A.)--Boston ...
Johnson, Lorand Victor
core +1 more source
Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]
, 2016 The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core +2 more sources
European Journal of Haematology, Volume 116, Issue 6, Page 850-862, June 2026.ABSTRACT Background Individuals with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) face transformation risks to acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). While older age is linked to increased risk, it remains unclear whether risk increases with age or with disease duration.
Nurgul Batyrbekova +5 more
wiley +1 more source